for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Checkpoint Therapeutics Inc

CKPT.OQ

Latest Trade

2.04USD

Change

-0.07(-3.32%)

Volume

4,995

Today's Range

2.02

 - 

2.07

52 Week Range

1.50

 - 

5.17

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.11
Open
2.05
Volume
4,995
3M AVG Volume
1.26
Today's High
2.07
Today's Low
2.02
52 Week High
5.17
52 Week Low
1.50
Shares Out (MIL)
38.00
Market Cap (MIL)
77.13
Forward P/E
-3.14
Dividend (Yield %)
--

Latest Developments

More

Checkpoint Therapeutics Says Q2 Loss Per Share $0.15

Checkpoint Therapeutics Q1 Loss Per Share $0.18

Checkpoint Therapeutics Announces Positive Interim Clinical Results Of Anti-Pd-L1 Antibody Cosibelimab

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.

Industry

Biotechnology & Drugs

Contact Info

2 Gansevoort St Fl 9

+1.212.5544366

http://www.checkpointtx.com

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019(E)

0.0K
EPS (USD)

2019(E)

-0.648
Price To Earnings (TTM)
--
Price To Sales (TTM)
17.38
Price To Book (MRQ)
10.41
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-214.45
Return on Equity (TTM)
-143.25

Latest News

Latest News

BRIEF-Checkpoint Therapeutics files for mixed shelf offering of up to $100 mln - SEC filing

* Checkpoint Therapeutics Inc - files for mixed shelf offering of up to $100 million - SEC filing Source text: (http://bit.ly/2zKSDGZ) Further company coverage:

BRIEF-Checkpoint Therapeutics receives orphan drug designation for CK-101

* Checkpoint Therapeutics receives orphan drug designation for ck-101 for the treatment of egfr mutation-positive non-small cell lung cancer

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up